CAMBRIDGE, Mass. - Biogen Inc. (NASDAQ:BIIB) is set to present new findings from its Alzheimer's disease research at the International Conference on Alzheimer's and Parkinson's Diseases, which will be held in Lisbon, Portugal, and online from March 5-9. The data includes results on BIIB113, an oral molecule aimed at inhibiting tau aggregation, and insights into Alzheimer's mechanisms.
The company will share results from a study on BIIB113 involving healthy volunteers, indicating brain target engagement and safety profiles. This molecule is part of Biogen's broader effort to explore multiple Alzheimer's pathologies. Additionally, Biogen's investigational antisense oligonucleotide, BIIB080, targets tau reduction.
Other key presentations will cover the long-term efficacy of lecanemab, an Alzheimer's treatment, and the role of alpha-synuclein pathology in the disease's progression, potentially guiding future research.
Biogen emphasizes its commitment to Alzheimer's research through these presentations, as part of its strategy to develop a comprehensive portfolio for Alzheimer's care. The company's pursuit of innovative treatments reflects its dedication to addressing the complexities of this disease.
These presentations are based on a press release statement and aim to inform about the latest advancements in Alzheimer's disease treatment research. Biogen is known for its pioneering science in biotechnology and focuses on delivering new medicines for patient care and shareholder value.
The information presented at the AD/PD conference will contribute to the understanding of Alzheimer's disease and may influence the direction of future clinical trials. Biogen's ongoing research and development activities are subject to the usual risks and uncertainties associated with drug development and commercialization.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.